Header image

ADVANCING TRANSPLANT INNOVATION: BRIDGING CLINICAL EXCELLENCE WITH SMARTER DRUG DEVELOPMENT

Tracks
AUDITORIUM MARGARITA SALAS
Wednesday, September 30, 2026
14:30 - 15:15
AUDITORIUM MARGARITA SALAS

Details

A silent storm is sweeping the globe: chronic kidney failure touches more than 850 million lives, ranks ninth among causes of death, and affects roughly 10% of the world’s population. In Spain alone, 15% of adults live with chronic kidney disease and about 68,000 people require dialysis or transplant to survive. Spain stands out as a beacon of transplant medicine — performing more than 6,000 kidney transplants a year and consistently leading the world in donor rates and clinical outcomes. Yet even a success story must evolve. To truly conquer organ shortages, extend long-term graft survival, and free patients from lifelong immunosuppression, bold innovation is essential. The horizon is already changing: xenotransplantation, advanced machine perfusion for organ preservation, robotic-assisted surgery (an area where Spain is a trailblazer), and AI-driven donor–recipient matching are reshaping what’s possible. Transplantation is re-emerging as a frontier of therapeutic invention, offering a rare opportunity to recast how drugs and biologics are developed for complex, high-stakes indications. Spain’s dense, high-volume clinical landscape offers an exceptional proving ground to accelerate next-generation drug development. By weaving together model-informed drug development, adaptive and innovative trial designs, and early regulatory alignment, we can shorten timelines, reduce development risk, and create more efficient clinical programs. The complexity of transplant studies — patient heterogeneity, long timelines, and shifting endpoints — demands this kind of nimble, collaborative approach. What’s needed now is stronger partnership between clinical centers, industry, regulators, and patient organizations to build an integrated ecosystem for transplant-focused innovation. The upcoming round table will explore how Spain can leverage its clinical excellence to become a global reference for transplant drug development, and how a forward-looking, coordinated strategy can turn today’s promise into tomorrow’s cures.


Speaker

Agenda Item Image
Pedro Carrascal
General Director
Platform of Patient Organisations. POP

Moderator

Agenda Item Image
Tabikh Ammar
Senior Medical Director, Clinical Development Global Medical Lead - Medical Strategy -Nephrology
CTI Clinical Trial & Consulting

.

Agenda Item Image
Isabel Portero
CSO & Founder
Biohope

.

loading